Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
fluconazole, Quantity: 2 mg/mL
Baxter Healthcare Pty Ltd
Fluconazole
Injection, solution
Excipient Ingredients: hydrochloric acid; sodium chloride; water for injections
Intravenous
1 x 50mL vial and 6 x 50mL vials
(S4) Prescription Only Medicine
FLUCONAZOLE-BAXTER Intravenous infusion should be used only when fluconazole cannot be administered orally: 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. Note: Data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (AIDS). 3. Treatment of oropharyngeal and oesophageal candidiasis in patients with AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (HIV) infection. 5. Vaginal candidiasis, when topical therapy has failed. 6. Serious and life-threatening Candida infections in patients who are unable to tolerate amphotericin B. Note: It remains to be shown that fluconazole is as effective as amphotericin B in the treatment of serious and life-threatening Candida infections. Until such data are available, amphotericin B remains the drug of choice.
Visual Identification: Clear, colourless solution.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius
Registered
2008-04-29
FLUCONAZOLE-BAXTER (Fluconazole) Version 2.0 1 of 23 AUSTRALIAN PRODUCT INFORMATION FLUCONAZOLE-BAXTER (FLUCONAZOLE) INJECTION FOR INTRAVENOUS INFUSION 1 NAME OF THE MEDICINE Fluconazole 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Fluconazole-Baxter, Injection for Intravenous Infusion is a clear colourless infusion containing 2 mg/mL of Fluconazole in 0.9% saline (sodium chloride dissolved in water for injection) solution. Each 100 mL of the solution contains 15.4 mmol of sodium. The pH of the solution is 4.0 – 8.0. Each 50 mL vial of solution contains 100 mg of fluconazole, each 100 mL vial of solution contains 200 mg of fluconazole and each 200 mL vial of solution contains 400 mg of fluconazole. Vials are for single use only. 3 PHARMACEUTICAL FORM Injection for intravenous infusion. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Fluconazole-Baxter Intravenous Infusion should be used only when fluconazole cannot be administered orally. 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. NOTE: Data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. 3. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with HIV infection. 5. Serious and life-threatening _Candida_ infections in patients who are unable to tolerate amphotericin B. NOTE: It remains to be shown that fluconazole is as effective as amphotericin B in the treatment of serious and life-threatening _Candida_ infections. Until such data are available, amphotericin B remains the drug of choice. 6. Vaginal candidiasis, when topical therapy has failed. 4.2 DOSE AND METHOD OF ADMINISTRATION DOSAGE Fluconazole is normally administered orally. If oral administration is not possible, it may be administered by intraven Read the complete document